[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$ptnt
$PTNT announces positive preclinical data for oral MC4R agonist PL7737 in an animal model of obesity. The drug showed rapid weight loss in the study.
About $ptnt
Palatin Technologies ($PTNT) is a biotechnology company.
Insights #
- $ptnt creators is up XXX% from the previous week.
- $ptnt mentions is up XXX% from the previous week.
- $ptnt Creators hit a high of X for the day
- $ptnt Creators hit an all time of X for the day
Engagements: XX #
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XXX
1 Month: XXXXX +101%
1-Year High: XXXXX on 2025-05-12
1-Year Low: X on 2025-07-06
| Social Network | X |
|---|---|
| Engagements | XX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: X +800%
1 Month: XX +67%
1-Year High: X on 2025-06-18
1-Year Low: X on 2025-05-08
| Social Network | X |
|---|---|
| Mentions | XX |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $ptnt in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
1 Week: X +700%
1 Month: XX +71%
1-Year High: X on 2025-07-19
1-Year Low: X on 2025-05-08
Sentiment: XX% #
Sentiment 24-Hour Chart Data
Current Value: XX%
Daily Average: XX%
1 Month: XX% -XX%
1-Year High: XXX% on 2025-06-18
1-Year Low: XX% on 2025-07-20
Most Supportive Themes
- Positive Preclinical Data: (100%) Palatin Technologies' oral MC4R agonist PL7737 shows positive preclinical data in obesity model.
Most Critical Themes
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | X | XX% | X | XX% | X | XX% |
| Total | X | XX% | X | XX% | X | XX% |
Top topics mentioned In the posts about $ptnt in the last XX hours
weight loss, welcome to, $kdozf, $pure, $taoif, rat, monk, otc, new york stock exchange, $ptn, empire
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$PTNT Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity"
@MaisaCorp on X 2025-07-15 21:21:09 UTC 3116 followers, XXX engagements
"$PTNT Oral MC4R Agonist PL7737 Shows Positive Preclinical Data in Obesity Model ➡ According to the announcement Palatin Technologies' oral MC4R agonist PL7737 demonstrated significant weight loss in preclinical studies using a diet-induced obese rat model. ➡ Monotherapy with oral PL7737 resulted in rapid weight loss with a high dose achieving XX% weight loss after just X days of treatment based on the announcement. ➡ The combination of oral PL7737 and tirzepatide showed additive effects leading to a XX% weight loss with the high dose combination according to the announcement. ➡ Palatin is"
@MarketPulse360 on X 2025-07-15 12:03:30 UTC XX followers, XX engagements
"$PTNT Palatin Technologies announced positive preclinical efficacy data for its oral MC4R agonist PL7737 in an animal model of obesity. According to the announcement PL7737 monotherapy resulted in rapid & significant weight loss after only X days of treatment. The study also showed the combination of oral PL7737 and tirzepatide led to additive weight loss effects. Palatin is advancing an IND-enabling toxicology program with an IND submission planned for Q4 2025 and clinical data expected in 1H 2026. Palatin's President and CEO Dr. Carl Spana noted the potential for meaningful weight reduction"
@MonkofFinance on X 2025-07-15 12:01:31 UTC XXX followers, XX engagements
"$PTNT Palatin Technologies announces positive preclinical data for oral MC4R agonist PL7737 in an animal model of obesity. PL7737 monotherapy produced rapid weight loss with additive effects when combined with tirzepatide. An IND submission is planned for Q4 2025 with clinical data expected in H1 2026. -- Paid Ad via #WallStWire: This account is operated by Wall Street Wire. Palatin Technologies or a related party has paid Wall Street Wire for ongoing promotional services. Full disclosures: Our content is not financial advice"
@FutureMarketsRT on X 2025-07-15 11:59:30 UTC XXX followers, XX engagements